TY - JOUR
T1 - Adherence to treatment in allergic rhinitis using mobile technology.
T2 - The MASK Study
AU - Menditto, Enrica
AU - Costa, Elisio
AU - Midão, Luis
AU - Bosnic-Anticevich, Sinthia
AU - Novellino, Ettore
AU - Bialek, Slawomir
AU - Briedis, Vitalis
AU - Mair, Alpana
AU - Rajabian-Soderlund, Rojin
AU - Arnavielhe, Sylvie
AU - Bedbrook, Anna
AU - Czarlewski, Wienczyslawa
AU - Annesi-Maesano, Isabella
AU - Anto, Josep M.
AU - Devillier, Philippe
AU - De Vries, Govert
AU - Keil, Thomas
AU - Sheikh, Aziz
AU - Orlando, Valentina
AU - Larenas-Linnemann, Désirée
AU - Cecchi, Lorenzo
AU - De Feo, Giulia
AU - Illario, M.
AU - Stellato, Cristina
AU - Fonseca, Joao
AU - Malva, Joao
AU - Morais-Almeida, M.
AU - Pereira, Ana Maria
AU - Todo-Bom, Ana Maria
AU - Kvedariene, Violeta
AU - Valiulis, Arunas
AU - Bergmann, Karl Christian
AU - Klimek, Ludger
AU - Mösges, Ralph
AU - Pfaar, Oliver
AU - Zuberbier, Torsten
AU - Cardona, Vicky
AU - Mullol, Joaquim
AU - Papadopoulos, Nikos G.
AU - Prokopakis, Emmanual P.
AU - Bewick, Mike
AU - Ryan, Dermot
AU - Roller-Wirnsberger, Regina E.
AU - Tomazic, Peter Valentin
AU - Cruz, Alvaro A.
AU - Kuna, Piotr
AU - Samolinski, Boleslaw
AU - Fokkens, Wytske J.
AU - Reitsma, Sietze
AU - Bosse, Isabelle
AU - Fontaine, Jean-François
AU - Laune, Daniel
AU - Haahtela, Tari
AU - Toppila-Salmi, Sanna
AU - Bachert, Claus
AU - Hellings, Peter W.
AU - Melén, Erik
AU - Wickman, Magnus
AU - Bindslev-Jensen, Carsten
AU - Eller, Esben
AU - O'Hehir, Robyn E.
AU - Cingi, Cemal
AU - Gemicioğlu, Bilun
AU - Kalayci, Omer
AU - Ivancevich, Juan Carlos
AU - Bousquet, Jean
AU - MASK study group
PY - 2019/4
Y1 - 2019/4
N2 - Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users. Conclusion and clinical relevance: Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.
AB - Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users. Conclusion and clinical relevance: Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.
KW - adherence
KW - mHealth
KW - mobile technology
KW - observational study
KW - rhinitis
KW - treatment
UR - https://www.scopus.com/pages/publications/85063011308
U2 - 10.1111/cea.13333
DO - 10.1111/cea.13333
M3 - Article
C2 - 30597673
SN - 0954-7894
VL - 49
SP - 442
EP - 460
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 4
ER -